Last updated: May 23, 2026
DARVOCET-N 100 (propoxyphene napsylate 100 mg with no additional strengths stated in the product name) is a discontinued opioid analgesic in the U.S. market. In the absence of current, registrant-level clinical development and active FDA regulatory change context, the commercial path is dominated by legacy exposure (if any residual distribution exists), versus substitution by other opioids and non-opioid analgesics. No actionable clinical-trials update for an ongoing DARVOCET-N 100 program can be produced from the available prompt context.
What is DARVOCET-N 100 and what is its current FDA regulatory status?
Answer: DARVOCET-N 100 is not an actively marketed, routinely prescribed opioid analgesic in the U.S.; it has been withdrawn/discontinued, which makes “clinical trials update” and “future revenue projection” mostly a residual-market exercise rather than an active launch or development story.
What active ingredient is DARVOCET-N 100?
- Propoxyphene napsylate (opioid analgesic)
- The “100” denotes a 100 mg strength in the product naming convention.
Why does current regulatory status matter for market projections?
For discontinued products, market size typically collapses after the last supply/marketing end point. Projections shift to:
- remaining channels (limited stock, alternative labeling, or residual dispensing in narrow geographies)
- substitution effects (replacement by other opioids such as hydrocodone/acetaminophen, oxycodone ER/IR, tramadol, tapentadol, and non-opioids)
- risk of no future growth base for new clinical data claims
Are there any active or ongoing clinical trials for DARVOCET-N 100?
Answer: No active, product-specific DARVOCET-N 100 clinical-trials update can be produced from the provided input context.
What would count as an actionable “DARVOCET-N 100 trial update”?
A usable update requires at least one of the following:
- an identifiable registered clinical trial record with current “recruiting”/“active, not recruiting” status tied to propoxyphene napsylate
- a defined new indication, formulation, or route supported by a registered protocol
- an FDA-related clinical development milestone (e.g., bridging study, REMS change, label update) tied specifically to DARVOCET-N 100
No such trial-identifying data is present in the prompt, so a precise update (trial IDs, phases, endpoints, timelines) cannot be generated.
When does DARVOCET-N 100 lose exclusivity, and what does that mean commercially?
Answer: Exclusivity-loss timing is not a practical driver for a discontinued product; the limiting factor is discontinuation/withdrawal rather than patent or exclusivity expiration.
What drives the post-discontinuation revenue curve?
- availability constraints (end of marketing, limited inventory)
- substitution (formulary decisions, guideline changes, payer policies)
- risk profile (propoxyphene-specific safety restrictions and opioid class pressures)
How do patent timelines affect a discontinued product?
Even if patents exist on certain formulations or uses, the revenue impact is usually already near-zero absent ongoing promotion and distribution. If DARVOCET-N 100 is discontinued, “loss of exclusivity” does not create a new generic entry cycle with measurable incremental sales.
What patents protect propoxyphene products, and which ones affect DARVOCET-N 100?
Answer: A complete, numbered patent estate mapping for DARVOCET-N 100 cannot be produced from the provided input context.
What you would normally extract for an IP-driven market projection?
- U.S. patents in the Orange Book (drug substance and formulation patents)
- method-of-use patents (indications and dosing regimens)
- exclusivity periods tied to approvals (if any remain relevant)
- Paragraph IV risk windows for generics
- litigation and settlements affecting launch timing
No such Orange Book or litigation identifiers are provided in the prompt.
What generic entry risks exist for DARVOCET-N 100?
Answer: If DARVOCET-N 100 is discontinued in the U.S., generic entry risk is not the correct framing. The main risk is whether any supply remains and whether other propoxyphene products persist in any channel.
How to interpret “generic risk” for a withdrawn brand
- For an actually discontinued product, “generic launch” tends to be irrelevant to brand sales.
- If propoxyphene remains available in any regulated form, competition becomes relevant but requires a product-by-product inventory, not a brand name alone.
How does DARVOCET-N 100 compare with other opioids and analgesics on market access?
Answer: DARVOCET-N 100 competes in a class where payer and guideline dynamics have shifted toward better-understood risk-benefit options and against higher-risk opioid profiles. Real-world prescribing favors alternatives depending on patient risk, comorbidities, and policy.
Substitution map likely to capture demand diverted from propoxyphene
- Hydrocodone/acetaminophen combinations
- Oxycodone formulations
- Tramadol and tapentadol (where appropriate)
- Non-opioid combinations and adjuvants (NSAIDs, acetaminophen, gabapentinoids in select settings, topical agents)
A quantitative replacement-share model cannot be computed without baseline DARVOCET-N 100 sales history and channel-specific market shares.
Market projection for DARVOCET-N 100: how to model revenue if the product is discontinued
Answer: A credible projection cannot be produced from the provided input context. For discontinued products, a “projection” typically becomes a residual inventory sell-through curve plus substitution erosion, which requires historical sales and supply availability data.
What a residual sell-through model needs
- last known wholesaler/retail sales months
- channel fill data (distribution timing)
- discontinuation date by NDC strength and package size
- competitor substitution shares by payer/formulary tier
- any remaining international availability (if the user cares beyond U.S. markets)
No such inputs exist in the prompt, so a numbers-based forecast would be fabricated.
Key takeaways
- DARVOCET-N 100 is not a current U.S. growth-market product; the business question is residual exposure and substitution, not a forward-looking clinical pipeline.
- A detailed clinical trials update cannot be generated from the provided context because no trial-identifying or status information is supplied.
- A numerical market projection cannot be produced without baseline sales, discontinuation timing, and current availability by NDC/channel.
FAQs
1) Is DARVOCET-N 100 still available in the U.S.?
Not as an actively marketed product in the routine prescribing context.
2) Are there any new FDA label updates for DARVOCET-N 100?
No such product-specific update information is provided in the input context.
3) What replaces demand when propoxyphene brands exit?
Other opioid analgesics and non-opioid alternatives, guided by payer rules and safety standards.
4) Does discontinuation eliminate the relevance of patents?
It reduces the commercial importance of exclusivity timing because marketing and distribution drive the revenue base.
5) How should investors interpret “clinical development” for discontinued opioid brands?
As mostly irrelevant unless there is a new, actively developed formulation, indication, or regulatory pathway tied to current submissions.
References
- U.S. Food and Drug Administration (FDA). Public drug safety communications and regulatory announcements related to propoxyphene products.
- U.S. Food and Drug Administration (FDA). Drug databases and regulatory status resources for approved opioid analgesics and historical product availability.
